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MEASURING THE PREVALENCE OF INTRADIALYTIC HYPOTENSION IN A SATELLITE DIALYSIS
CLINIC: ARE WE TOO COMPLACENT?

Abstract
Aims and objectives
Measuring the prevalence of symptomatic (S-IDH) and asymptomatic intradialytic hypotension (AIDH) or post-dialysis overhydration in a satellite haemodialysis clinic in Western Australia.

Background
Intradialytic hypotension is one of the most common side-effects of haemodialysis caused by
ultrafiltration provoking a temporary volume depletion. The prevalence of asymptomatic hypotension
during dialysis has been rarely reported, but is considered to have the same negative consequences
as symptomatic hypotension on various end organs like the brain and the gastro-intestinal tract.

Design
Observational study on a retrospective 3-month period of nurse - recorded fluid related adverse
events.

Methods
Data collection on the occurrence of S-IDH and A-IDH during a total of 2357 haemodialysis
treatments in 64 patients. Body weight of patients at the time of cessation of treatment was recorded,
and patients whose weight exceeded their ideal body weight by at least 0.5 kg, were classified as
overhydrated.
Data analysis was performed using SPSS version 24 software.

Results
Symptomatic intradialytic hypotension was the most common adverse event measured in this cohort,
and occurred during 221 (9.4%) of all treatments, whereas asymptomatic intradialytic hypotension
occurred in 88 (3.7%) of all treatments. Total occurrence of intradialytic hypotension was 13.1% and
symptomatic was observed in 30 patients, implying that nearly every second patient had at least one
symptomatic episode within three months. Overhydration occurred in a total of 103 (4.4%) of all
treatments, and involved 17 patients.

Conclusions
Symptomatic and asymptomatic intradialytic hypotension were the most commonly observed adverse
events in this cohort, overhydration occurrence was considerably less common.

Keywords
Symptomatic intradialytic hypotension, asymptomatic intradialytic hypotension, haemodialysis,
overhydration, fluid overload, satellite dialysis, renal nurses

Introduction
Despite numerous technical improvements, intradialytic hypotension (IDH) is still a classical problem
in satellite dialysis clinics. Previous literature has reported very divergent rates of occurrence, ranging
from 20-60%(Rocha, Sousa, Teles, Coelho, & Xavier, 2015; Schiller, Arramreddy, & Hussein, 2015).
There is more evidence emerging about the damaging effects of IDH (Chao, Huang, & Yen, 2015;
McIntyre, 2010) causing morbidity and increased mortality rates in haemodialysis patients(Flythe,
Xue, Lynch, Curhan, & Brunelli, 2015). Therefore, awareness of IDH warrants the attention of all renal
healthcare professionals involved in direct patient care (Ghaffar & Easom, 2015).
Primarily, each IDH event has a critical impact on the quality of life of haemodialysis patients and is
responsible for significant patient symptoms like cramps, fatigue, nausea and vomiting, dizziness and
loss of consciousness (S-IDH). Asymptomatic IDH (A-IDH) has been defined as a systolic blood
pressure (SBP) drop of 20 mmHg or more according to the National Kidney Foundation Kidney
Disease Outcomes Quality Initiative (KDOQI) guidelines(National Kidney Foundation Inc., 2005), but

without any clinical symptoms. Multiple definitions for IDH exist, ranging from intradialytic SBP drop
combined with nursing interventions like saline bolus administration and pausing of ultrafiltration.
(Flythe et al., 2015). Other IDH definitions focus solely on intradialytic SBP assessment with the
precondition of a SBP drop of 20-40 mmHg or nadir SBP of 90-100 mmHg (Dheenan & Henrich,
2001; Flythe et al., 2015). However, the combination of SBP fall with SBP nadir of less than 110
mmHg has also been commonly accepted as IDH definition (Flythe et al., 2015; Imai et al., 2006). IDH
also has damaging effects on a variety of organ systems. There is sufficient evidence that any event
of an IDH, either symptomatic or asymptomatic, qualifies as an ischemic insult (Bradshaw & Bennett,
2015; Daugirdas, 2015; Davenport, 2015). It has been reported that it adversely affects end organs
including the brain, gastrointestinal tract and the heart, and causes deterioration of residual kidney
function, as well as cardiac stunning and ischemic brain injury (McIntyre & Goldsmith, 2015). It has
also been linked to vascular access thrombosis (VAT), insufficient dialysis dose and mortality (Flythe
et al., 2015). In conclusion, IDH is harmful and every effort must be undertaken to avoid its
occurrence. Daugirdas (2015) suggested that by measuring the incidence of IDH, the quality of care
could be improved, as it would then come to the attention of renal healthcare providers who could
evaluate their existing IDH preventive methods. This measure could prompt quality improvement
measurements for the improved awareness, identification and prospective treatment of IDH. It could
also lead to important changes in policy and practice to reduce IDH prevalence.
As we try to achieve euvolemia during haemodialysis, using ultrafiltration, sometimes this goal cannot
be achieved for multiple reasons. This can result in post-treatment overhydration (OH), in some way
converse to IDH, and has been described as strongly linked to left ventricular hypertrophy (LVH) and
increased morbidity and mortality (Huang, Filler, Lindsay, & McIntyre, 2015).

Materials and Methods
Study design
Retrospective observational study of 64 patients over a period of 3 consecutive months from June to
August 2015. A total of 2357 dialysis treatments were investigated for the occurrence of S-IDH, A-IDH
and OH.

Setting, sample and data collection
A regional satellite haemodialysis unit in Western Australia (WA) was selected for this observational
study. Ethics approval was obtained by the South Metropolitan Health Service Human Research
Ethics Committee, the Human Research Ethics Committee of Edith Cowan University and the
Western Australian Aboriginal Health Ethics Committee prior to this project. Renal nurses in this unit
are required to create a patient progress report after each haemodialysis treatment. This report
contains information about transcribed pre- and post-treatment weight, ideal body weight (IBW),
ultrafiltration (UF) goal and multiple blood pressure recordings over the course of the haemodialysis
treatment. Any significant clinical events which were considered to be treatment related or indicative
of the current clinical condition, are also routinely recorded. Each patient progress report summarized
the course of the treatment. Events of S-IDH were documented, following the definition of the K/DOQI
guidelines (National Kidney Foundation Inc., 2005), as a fall in systolic blood pressure of at least 20
mm Hg together with at least two of the symptoms including abdominal discomfort, yawning, sighing,
nausea, vomiting, muscle cramps, restlessness, dizziness or fainting and anxiety. A-IDH was
recorded where the systolic blood pressure fell at least 20 mmHg, but with no further recorded clinical
symptoms in the patient progress report. Patients were classified to be OH, when their post-treatment
weight exceeded at least 0.5 kg of their IBW.

Study population
Patients with chronic kidney disease attended maintenance haemodialysis three times per week, one
group of patients attended the clinic for haemodialysis on Monday, Wednesday and Friday (MWF)
and the other group attended on Tuesday, Thursday and Saturday (TTS). Demographic data were
recorded for each participant, and included: gender, age, ethnicity (self-declared), cause of kidney
disease and socio-economic status (SES). The definition of SES was taken from the “Postal Area
(POA) Index of Relative Socio-economic Advantage and Disadvantage, 2011” released by the
Australian Bureau of Statistics under the Socio-economic Indexes for Areas (SEIFA). Patients were
coded according to the SEIFA index corresponding to their residential postcode and classified as
belonging to either “lower”, “lower-medium”, “upper-medium” or “high” socio-economic status.
Comparison of the groups (MWF and TTS) with respect to their demographic data was performed

using the Chi-square test or t-test as appropriate. Occurrence of outcomes (SIDH, AIDH, and OH)
following each treatment were analyzed using a generalized estimating equation (GEE). This model
was used so that correlations between outcomes for treatments belonging to the same patient could
be taken into account. Similarly, to a logistic regression, the results of the GEE model were
expressed as odds ratios, their 95% confidence intervals and p-values. The GEE model was used to
assess possible relationships between the independent variables (demographic variables as well as
month, day of treatment, day number of treatment, duration of treatment) and the occurrence of any
IDH (S-IDH or A-IDH), and OH. Data analyses were conducted using the SPSS version 24 statistical
software, and, following convention, a p-value<0.05 was taken to indicate a statistically significant
association in all tests.

Results
There were 64 patients included for study: 45 (70.3%) male and 19 females (29.7%). Patients were
predominantly Caucasian (61%) or Indigenous Australian (IA) (20%). There were 34 patients treated
on MWF, and 30 on TTS, and these 2 groups were found to be similar for all baseline characteristics
(Table 1). Mean age overall was 63.0 years (SD 15.8), with most ages ranging from 48 to 72 years
except for some skewness towards the older age groups (two patients were older than 88 years).
Table1. Baseline demographics of MWF and TTS group (person-based)
MWF group
TTS group
(n= 34)
(n=30)
Male, n (%)
Female, n (%)
Age, (yr)
Mean (SD)
Race, n (%)
Caucasian
Australian Aboriginal
Asian
Indonesian
Indian
Tongan
Cause of ESRD, n (%)
Diabetes mellitus
Glomerulonephritis
Hypertension
Reflux nephropathy
Polycystic kidney disease
Alport syndrome
FSGS
Nephropathy unknown gen.
Ischemic nephropathy post AAA repair
Renal cell ca
Vasculitis
Pyelonephritis
Treatment Duration, n (%)
3 hr
3.5 hr
4 hr
4.5 hr
5 hr

Total
(n=64)

p Value

25 (73.5)
9 (26.5)

20 (66.7)
10 (33.3)

45 (70.3)
19 (29.7)

0.55

62.6 (16.5)

63.3 (15.3)

63 (15.8)

0.86*
0.3

18 (52.9)
6 (17.6)
6 (17.6)
2 (5.9)
1 (2.9)
1 (2.9)

21 (70)
7 (23.3)
2 (6.7)
0
0
0

39 (60.9)
13 (20.3)
8 (12.5)
2 (3.1)
1 (1.6)
1 (1.6)
0.73

11 (32.4)
9 (26.5)
3 (8.8)
3 (8.8)
2 (5.9)
2 (5.9)
1 (2.9)
1 (2.9)
1 (2.9)
1 (2.9)
0
0

7 (23.3)
7 (23.3)
5 (16.7)
4 (13.3)
3 (10)
0
1 (3.3)
1 (3.3)
0
0
1 (3.3)
1 (3.3)

18 (28.1)
16 (25)
8 (12.5)
7 (10.9)
5 (7.8)
2 (3.1)
2 (3.1)
2 (3.1)
1 (1.6)
1 (1.6)
1 (1.6)
1 (1.6)

1 (2.9)
1 (2.9)
24 (70.6)
4 (11.8)
4 (11.8)

1 (3.3)
2 (6.7)
20 (66.7)
2 (6.7)
5 (16.7)

2 (3.2)
3 (4.8)
43 (68.3)
6 (9.5)
9 (14.3)

0.88

Baseline demographics were similar in both patient cohorts with a similar distribution of the causes of
end-stage renal disease (ESRD). The most common causes of ESRD were diabetes mellitus,
glomerulonephritis and hypertension, followed by reflux nephropathy and polycystic kidney disease.
No significant difference was observed between groups for cause of renal failure (χ2 = 7.76, df = 11, p
= 0.73). Most patients received 4 h haemodiafiltration (HDF) per treatment, while significantly less
attended 4.5 or 5 h treatment. Only five patients were on a schedule of 3.5 h or less. Again, there was
no significant difference between the groups when observing for treatment duration (χ2 = 1.18, df = 4,
p = 0.88). (Table1)
S-IDH occurred during 221 treatments and A-IDH was observed during 88 treatments, resulting in a
total of 309 (13.1%) treatments with any form of IDH. OH developed less frequently, in only 103 of all
treatments (4.4%) and only in 17 patients, but interestingly 11 of the OH patients also had IDH
episodes on different days. 6 patients had repeated OH episodes. More than half of all patients had at
least one episode of IDH during the observation period, while a third had at least two or more IDH
episodes. With increasing duration of the dialysis session, a higher frequency of IDH events was
observed. The highest incidence of S-IDH or A-IDH was 23.6%, observed in the patient group
receiving 4.5 h treatment, followed by the 5 h treatment group with an incident rate of 22.3% of all
treatments. Shorter treatments of 3 to 4 h had significantly fewer IDH episodes. There was a
significant difference between various treatment durations for the occurrence of any IDH (χ2 = 65.35,
df = 4, p <0.001). In contrast, the shorter the treatment, the more OH events occurred, peaking at
18.6% OH in the 3 h group, also demonstrating a significant difference between treatment durations
(χ2 = 53.03, df = 4, p <0.001). Females had a higher rate of IDH than male patients (χ2 = 6.45, df = 1, p
= 0.01). At the time of leaving the dialysis unit, females also had slightly more episodes (5.1%) of
overhydration than males (4.1%), but with no statistically significant difference.
Most episodes of IDH developed in patients with diabetes and hypertension, followed by those with
glomerulonephritis and reflux nephropathy (Χ2 =15.25, df = 4, p = 0.04). Polycystic kidney disease,
focal segmental glomerulosclerosis (FSGS) ranked much lower with only 2 to 8 % of all treatments.
Interestingly, two patients with Alport syndrome had the highest occurrence of OH, followed by
patients with hypertension and diabetes mellitus (Χ2 =51.06, df = 11, p <0.001).
With regard to ethnicity, it was observed that IAs experienced the highest occurrence of IDH events.
Caucasian patients had slightly fewer IDH events, but without a significant difference between these
groups. However, patients of Asian origin showed an event rate of IDH which was significantly lower
than both IAs and Caucasians (Χ2 = 14.28, df = 2, p= 0.001). Asian patients also had the lowest event
rate of OH compared to all other ethnicities. In contrast, most OH events occurred in IAs followed by
Caucasians (Χ2 = 25.8, df = 2, p<0.001).
There were only marginal differences in events across months. August had a slightly higher event rate
of IDH than June and July. This was similar for OH. The highest occurrence of IDH was noted on a
Friday, followed by Monday and Saturday. (Table2)
Table2. Occurrence of S-IDH, A-IDH, any IDH and OL (treatment-based)
N
S-IDH
A-IDH
Treatments, n (%)
Female, n (%)
Male, n (%)
Duration, n (%)
3h
3.5 h
4h
4.5 h
5h
Cause of ESRD, n (%)
Diabetes mellitus
Hypertension
Glomerulonephritis

2357 (100)

Any IDH

OH

680 (28.9)
1677 (71.1)

221 (9.4)
75 (11)
146 (8.7)

88 (3.7)
33 (4.9)
55 (3.3)

309 (13.1)
108 (15.9)
201 (12)

103 (4.4)
35 (5.1)
68 (4.1)

86 (3.6)
114 (4.8)
1564 (66.4)
238 (10.1)
355 (15.1)

7 (8.1)
10 (8.8)
126 (8.1)
33 (13.9)
45 (12.7)

2 (2.3)
3 (2.6)
26 (1.7)
23 (9.7)
34 (9.6)

9 (10.4)
13 (11.4)
152 (9.8)
56 (23.6)
79 (22.3)

16 (18.6)
1 (0.9)
53 (3.4)
17 (7.1)
16 (4.5)

658 (27.9)
278 (11.8)
606 (25.7)

78 (11.9)
30 (10.8)
47 (7.8)

33 (5)
10 (3.6)
28 (4.6)

111 (16.9)
40 (14.4)
75 (12.4)

40 (6.1)
21 (7.6)
12 (2)

Reflux nephropathy
Polycystic kidney disease
FSGS
Alport syndrome
Nephropathy unknown gen
Ethnicity, n (%)
Caucasian
Indigenous Australian
Asian
Month of year, n (%)
June
July
August
Day of week, n (%)
Monday
Tuesday
Wednesday
Thursday
Friday
Saturday

271 (11.5)
170 (7.2)
79 (3.4)
77 (3.3)
218 (9.2)

26 (9.6)
7 (4.1)
3 (3.8)
2 (2.6)
0

4 (1.5)
2 (1.2)
3 (3.8)
0
0

30 (11.1)
9 (5.3)
6 (7.6)
2 (2.6)
0

9 (3.3)
2 (1.2)
0
11 (14.3)
4 (5.7)

1416 (60.1)
492 (20.9)
449 (19)

141 (10)
57 (10.8)
23 (5.5)

47 (3.3)
30 (5.7)
11 (2.7)

188 (13.3)
87 (16.5)
34 (8.2)

52 (3.7)
43 (8.2)
8 (1.9)

798 (33.9)
809 (34.3)
750 (31.8)

58 (7.7)
69 (8.5)
94 (11.8)

29 (3.9)
25 (3.1)
34 (4.3)

87 (11.6)
94 (11.6)
128 (16.1)

34 (4.5)
30 (3.7)
39 (4.9)

407 (17.3)
373 (15.8)
397 (16.8)
366 (15.5)
405 (17.2)
409 (17.4)

45 (10.3)
33 (8.8)
31 (7.8)
32 (8.7)
38 (9.4)
42 (11.1)

20 (4.6)
11 (2.9)
15 (3.8)
10 (2.7)
23 (5.7)
9 (2.4)

65 (14.9)
44 (11.8)
46 (11.6)
42 (11.5)
61 (15.1)
51 (13.5)

37 (8.5)
26 (7)
16 (4)
8 (2.2)
10 (2.5)
6 (1.6)

Monday and Tuesday had the highest occurrence rates for any IDH with 14.0%, followed by Friday
(MWF) and Saturday (TTS) (13.8% combined). The midweek-day had the least occurrence of IDH in
both groups with 11.5%, demonstrating significant difference. There was a series of treatments which
were scheduled for a Sunday. These showed an unusual level of increase in IDH events. As this was
not part of the normal process of regular dialysis treatments, we removed them from data analysis.
OH was most frequent on Mondays in the MWF group and Tuesdays in the TTS group (Table3).
Table3. Occurrence of S-IDH, A-IDH, any IDH and OL in the combined MWF and TTS groups
(treatment-based)
Treatments
S-IDH
A-IDH
Any IDH
OH
Events during treatments
per Days of week, n (%)
Monday and Tuesday
780 (33.1)
78 (10.0)
31 (4.0)
109 (14.0)
63 (8.1)
Wednesday and Thursday 763 (32.3)
63 (8.3)
25 (3.3)
88 (11.5)
24 (3.2)
Friday and Saturday
814 (34.6)
80 (9.8)
32 (3.9)
112 (13.8)
16 (2.0)
A Generalized Estimating Equation (GEE) was performed to assess the impact of several factors on
the likelihood of the event of any form of IDH. The model initially contained 10 independent variables
(gender, age, ethnicity, cause, duration of treatment, month of year, day of treatment, day of
treatment, socio-economic status and group). An exchangeable variance structure was used to
model the intra-patient correlations, and the method of backward elimination was used to exclude
non-significant results. The final model to investigate the occurrence of any form of IDH contained the
predictors gender, age, cause, month of year, day of treatment and duration (Table4).
Table4. Generalized Estimating Equation (GEE) model predicting likelihood of any IDH events
by gender, age, ethnicity, cause, group, day of week, month, day of treatment, duration and
socio-economic status
Predictor
Patient’s Gender
Female
*Male

Number (%) of
any IDH
events
N(%)

Odds Ratio
(OR)

108 (15.9)
201 (12)

1.71
1 (reference)

95% C.I.
Lower
1.001
.

p-value
Upper
2.92
.

0.050
.

Patient’s Age
24 -90 years

309 (13.1)

1.02

1.001

1.04

0.038

Glomerulonephritis

75 (12.4)

0.44

1.22

2.88

0.004
0.020

Hypertension

40 (14.4)

0.84

0.34

2.04

0.693

Reflux Nephropathy
Other
*Diabetes

30 (11.1)
17 (8.3)
111 (16.9)

1.21
0.58
1 (reference)

0.51
0.27
.

2.89
1.26
.

0.662
0.166
.

Cause

Month
*June
July
August
Day of treatment
*Monday or Tuesday
Wednesday or
Thursday
Friday or Saturday
Duration
3 h/ 3.5 h
*4 h
4.5 h
5h

87 (11.6)
94 (11.6)
128 (16.1)

1 (reference)
1.002
1.54

.
0.75
1.05

.
1.38
2.26

0.033
.
0.992
0.027

109 (13.4)

1 (reference)

.

.

0.371
.

88 (11.6)

0.84

0.62

1.14

0.266

112 (14.3)

1.06

0.76

1.46

0.739

22 (10.9)
152 (9.8)
56 (23.6)
79 (22.3)

1.1
1 (reference)
3.08
3.6

1.08
.
1.47
1.82

1.36
.
6.45
7.12

<0.001
0.032
.
0.003
<0.001

Note: * variable used as the reference variable.

The results of this model showed that females had almost twice the odds of experiencing any form of
IDH in comparison to males. Patients with glomerulonephritis had significantly lower odds of an IDH
event when compared to those with diabetes. There was also a much higher likelihood of IDH in
August than in June or July. While no statistical significance was found for the day of treatment,
treatment duration had an important impact on predicting IDH. Longer treatment hours had a threefold
higher chance of IDH in the 4.5 h group and 3.6-fold higher in the 5 h group respectively, in
comparison to the 4 h patient group. Patients receiving 3 h treatment had 10% higher chance of
experiencing IDH. There was no statistical significance when observing for day of treatment, ethnicity,
group or socio-economic status.

A GEE model was also applied to predict the probability of postdialytic overhydration (OH) initially
using the same independent variables as in the previous model for IDH. By eliminating the nonsignificant results the final model contained the variables age, duration, day of treatment and cause
(Table5).
Table5.Generalized Estimating Equation (GEE) model predicting likelihood of overhydration (OH)
events by gender, age, ethnicity, cause, group, day of week, month, day of treatment, duration and
socio-economic status
Predictor

Number (%) of
OH events
N(%)

Odds Ratio
(OR)

103 (14.4)

1.06

1.03

1.09

<0.001

63 (7.7)

5.65

2.14

14.93

<0.001

24 (3.1)

1.38

0.57

3.34

0.476

16 (4.1)

1 (reference)

.

.

.

52 (3.7)

1 (reference)

.

.

.

95% C.I.
Lower

p-value
Upper

Patient’s Age
24 -90 years
Day of treatment
Monday or Tuesday
Wednesday or
Thursday
*Friday or Saturday
Ethnicity
Caucasian

Indigenous Australian
Other

43 (8.2)
8 (1.9)

1.94
0.47

1.46
0.83

11.97
5.54

0.008
0.113

3 h / 3.5 h

17 (18.9)

0.05

1.32

2.89

<0.001

4h

53 (3.4)

0.53

0.23

1.20

0.129

4.5 h
*5 h

17 (7.1)
16 (4.5)

0.14
1 (reference)

1.57
.

3.88
.

<0.001
.

40 (6.1)
21 (7.6)
12 (2)
9 (3.3)
17 (7)

0.35
0.15
1.12
0.83
1 (reference)

0.12
1.34
0.22
0.25
.

1.01
3.63
5.62
2.77
.

0.051
0.010
0.892
0.763
.

Duration

Cause
Diabetes mellitus
Hypertension
Glomerulonephritis
Reflux Nephropathy
*Other

Note: * variable used as the reference variable.

Interestingly, this model revealed that patients had a more than 5 times higher chance to be
overhydrated after the dialysis treatment on the first day of the week (Monday or Tuesday) than on a
Friday or a Saturday). Patients receiving 3 h treatment had only a small, but statistically significant
chance for the occurrence of postdialytic OH in comparison to patients receiving 5h treatment.
Similarly, patients receiving 4.5 h treatment had a 14% higher likelihood of experiencing OH after their
treatment. Diabetics and hypertensive patients had a higher risk of experiencing OH, compared to
other causes. IA had almost double the risk than Caucasians to experience OH.

Discussion
This is the first study investigating the prevalence of S-IDH, OH and particularly A-IDH in a patient
cohort over three months. As A-IDH has detrimental effects on various organ systems similarly to SIDH, we considered it important to also investigate its occurrence. Combining the prevalence of A-IDH
(3.7%) and S-IDH (9.4%) resulted in a total IDH prevalence of 13.1%, significantly greater than the
occurrence of OH (4.4%). This highlights the magnitude of the IDH problem. Current National Kidney
Foundation Kidney Disease Outcomes Quality Initiative (NKF-KDOQI) guidelines (National Kidney
Foundation Inc., 2005) contain only recommendations for goals of pre- or postdialysis blood
pressures, but do not recommend any frequency for monitoring intradialytic blood pressure
measurements. When intradialytic blood pressure measurements are not performed routinely and
continuously by nurses as standard practice, and if patients do not display any symptoms, A-IDH
might occur frequently and yet remain undetected (Horkan, 2013). Moreover, some authors
recommend intervening in the event of A-IDH as a pre-emptive method to improve long-term
outcomes for patients and to decrease morbidity and mortality (Bradshaw & Bennett, 2015). Some
authors have posited ”…that the dialysis community has tacitly accepted that IDH is an innate feature
of the HD treatment “(Schiller et al., 2015, p. 233) and is therefore not focused on its prevention and
early identification. This highlights the need to also capture A-IDH events when analyzing IDH.
The study cohort of 64 patients included a relatively small number of female patients (n=19), but our
results showed a higher percentage of IDH events amongst females than males. This is congruent
with previous research where most IDH events occurred in older, female and diabetic patients (Sands
et al., 2014). Our GEE model also confirmed this trend, where females had almost double the risk of
experiencing an IDH compared to males (OR=1.71, 95% CI:1.001-2.92, p=0.05). As the reference
group in the model, diabetics had not only the highest number of IDH events, but they also had the
highest risk of suffering from IDH than any other disease group.
S-IDH peaked in the 4.5 h group and A-IDH peaked in the 5 h group. These findings were also
confirmed by the GEE model. Patients receiving 3 h treatment had only a 35% reduced chance of any
form of IDH (OR=0.65, 95% CI:0.44-0.96, p=0.03). In contrast, an individual with the maximum of 5 h
treatment duration had more than 3.5 times the chance of experiencing IDH (OR=3.6, 95% CI:1.827.12, p<0.01). These findings stand in stark contrast with some authors who suggest, that an

expansion of treatment time, generally or on an individual basis, should reduce the incidence rate of
IDH (Agar, 2016; Hossli, 2005) as this should reduce the ultrafiltration rate per hour. The higher
occurrence of IDH episodes may be explained by large interdialytic weight gains (IDWG) resulting in
higher ultrafiltration rates in some of the patients in our study. This assumption correlates with the
findings of Schulz et al. (2007), where fewer episodes of IDH in patients with IDWG <1.5kg/2days
were described. This is consistent with the findings of Santos, Peixoto, and Perazella (2012) where
excessive IDWG was associated with more events of IDH. However, it is not unlikely that other
additional factors, like intradialytic food intake, especially during increased treatment times or
incorrect IBW might have contributed to a higher prevalence.
The policy of the dialysis unit in our study allowed for a maximum ultrafiltration rate (UFR) of 1000ml/h
for each patient within the cohort, regardless of their individual IBW. While this might work for some
patients well, it might be difficult for others, especially if their IBW is much lower than 100kg. Where
UF removes too much intravascular plasma water, or removes it too rapidly, intravascular
hypovolaemia may result (Caplin, Kumar, & Davenport, 2011). IDH is thought to be a direct
consequence of this imbalance between excessive intravascular fluid removal and inadequate
passive plasma refilling (Davenport, 2006). This is confirmed by Agar (2016) who has argued that
extending treatment time would allow for additional time to remove fluid safely, especially for patients
with larger IDWG. Agar (2016) also stresses the importance of an individual fluid removal (UFR) rate
of only ≤10 ml/kg/hour as beyond that value morbidity, including hypotension, increases significantly.
He further proposed a rather individualized treatment duration approach to minimize the risk of
hypoperfusion of end organs. This recent and individualized approach is supported by several other
authors (Flythe & Brunelli, 2011; Huang et al., 2015; Ludvigsen, Hermansen, & Lindberg, 2015). It is
possible that in this study, some of the IDH events may have been caused by an unnecessarily high
UFR. An individually tailored UFR approach could potentially mean fewer IDH events in the future for
patients with extended treatment hours.
The comparatively low occurrence rate of OH post treatment demonstrates that most patients left the
dialysis unit more often “dry” than “wet”. This trend is also confirmed by the lowest OH occurrence on
the last day of the week in both groups (MWF=2.5% and TTS=1.6%) compared to Monday
(MWF=8.5%) and Tuesday (TTS=7%). This is, on the one hand, a result of everyone’s efforts to
achieve a maximum fluid removal per treatment by the end of the week, so it should be considered
the most desirable outcome. On the other hand, seeing this in the light of the high number of events
of IDH, it could reflect a poor outcome with an initially “good” treatment intention. The high risk of OH
(OR5.65, 95%CI:2.14-14.93, p<0.01) on the first day of the week, seen in our results, could have
several causes. Firstly, during the longer interval of the weekend, patients with little to no residual
output function have simply more time to accumulate excess fluid. Secondly, as a precaution, nurses
might not want to achieve exact IBW readings post-treatment already on the first day of the week,
when a patient initially does not show any significant clinical signs of OH. Therefore, a nurse could
then allow for a reduced or moderate UF goal, as the next treatment will follow after a relatively short
time interval.
The highest frequency (16.5%) of any IDH episodes was noted amongst IAs. There are several
factors that could influence this. It was noted that some patients in this group had repeatedly missed
their regular scheduled treatment. For this reason, on the subsequent scheduled treatment they had
more fluid to be removed to regain euvolemia, but concurrently had a higher risk of experiencing IDH
with this temporarily larger IDWG. Considering that, of all ethnic groups, they also had the highest
incidence rate of OH post treatment, it may have been the case that this patient group encountered
more difficulty in adhering to fluid restriction and avoiding excessive oral fluid intake. Confirming this,
the model revealed that IAs had nearly twice the risk compared to Caucasians of finishing their first
treatment of the week overhydrated. Another reason for this fact could be a miscommunication
between the nurses and IA when overhydration occurs. Cass et al. (2002) reported that
miscommunication is common between non-indigenous health care professionals and Indigenous
patients in haemodialysis units. Their study highlighted that this communication needs to improve for
patients to better understand and adhere to treatment goals and that “fundamental change is required
for Aboriginal patients to have significant input into the management of their illness” (Cass et al.,
2002).
Excess fluid volume has been previously described as being directly associated with hypertension
(Çelik, Kara, Yilmaz, & Apiliogullari, 2011) and an increased post dialytic blood pressure has been

correlated with elevated hydration status (Nongnuch et al., 2015). Conversely, Takeda, Toda, Fujii,
Sasaki, and Matsui (2006) reported that additional antihypertensive medications, decreasing pre- and
intradialytic blood pressures, was not associated with an increase in the frequency of IDH. These
authors concluded that there is no correlation between predialytic and intradialytic blood pressure and
the incidence of IDH. Interestingly we found in our study a high number (14.4%) of IDH events in
patients with hypertension. This could be possibly caused by the nurses’ assumption of hypertension
being caused by excess fluid. Consequently, overestimating ultrafiltration goals and concurrently
unaware of the genuine intravascular volume status of a patient, which could not have been validated
as there were no tools for its specific measurement on hand. As sometimes excess fluid shows in
some patients as a symptom of hypertension, some renal nurses may tend to assume that
hypertension may always be a sign of hypervolemia. As then there are no other objective parameters
available to assess intravascular volume, they may then tend to challenge the patients’ dry weight,
subsequently trying to remove more fluid, ultimately with the result of an IDH event. Additionally, the
majority (65%) of the 17 overhydrated patients also had episodes of IDH during other treatments.
This may either be due to unsuccessful attempts to remove excess fluid, or incorrectly assessed IBW.

Limitations
As an observational study, patients in this study were not randomized to their treatment days so the
findings are not generalizable to the broader population. This study did not collect any data
concerning the dialytic age, antihypertensive medication and the residual urine output from the
patients. IBW assessments and adjustments during the study period were based only on clinical
findings (the nurse’s clinical assessment and BP measurements) therefore OH findings could not be
validated with bioimpedance method.

Conclusion
IDH remains one the foremost adverse events for patients receiving haemodialysis. Adding the events
of A-IDH, which may be generally underreported, to S-IDH, emphasizes the issue of IDH. Our study
has confirmed that the problem of IDH is not only common, but even greater when A-IDH is included,
increasing the total number of IDH episodes by almost a third. Modelling revealed that females had
almost twice the risk of an IDH event, and patients with 4.5 h or more treatment time had more than
three times the risk of an IDH event. It may be that this increased risk correlates with the general
maximum UFR of 1000ml/h for every patient in our study unit, irrespective of their IBW. This
undifferentiated approach has been associated with detrimental effects in previous studies. OH was
significantly less frequently observed than IDH. Further, due to the lack of accurate and objective
parameters for volume assessment, renal nurses can sometimes only roughly estimate how much UF
could be too much for the patient they treat. Future research on the prevalence of IDH will need to
include residual output of the participants as this may have a direct effect on the definition of UF goals
which will subsequently affect the likelihood of IDH events. Dialysis units need more preventive
strategies in place to reduce the prevalence of IDH and to improve health outcomes for patients.
Anecdotally, unit specific policies for IBW adjustment, maximum UFR and intervention protocols on
symptomatic and asymptomatic IDH seem to vary greatly between dialysis units worldwide, but
probably have a significant influence on the incidence of IDH. Most importantly, renal nurses and
other healthcare providers in haemodialysis must be made aware of the existence of A-IDH and SIDH and their adverse effects. Knowledge about the frequency of these events and patients most at
risk can potentially increase their understanding of the “bigger picture” and long-term effects of the
treatment they provide. Drawing their attention to this obvious problem could be one of the key
features of future efforts to improve outcomes for patients. As renal nurses initiate treatments, decide
on UF goals, UFR and constantly observe patients during haemodialysis, they need to be better
equipped with knowledge about fluid shifts and the negative impact of IDH, whether combined with
symptoms or not. Realizing and acknowledging the limitations of maximum UFR for each patient
could potentially lead to beneficial changes in how renal nurses decide each day on treatment goals.
Furthermore, use of existing and new objective fluid assessment tools like bioimpedance
measurements (Body Composition Monitor – BCM Fresenius) or ultrasound of the inferior vena cava
on a broader scale by more nurses could possibly result in better health outcomes. In summary, this
has potential to increase the discussion amongst nurses and their patients at handover treatments

and upon treatment initiation. Therefore, all relevant aspects of the decision-making process by
nurses upon treatment initiation should be a most important subject for future research studies.
The results of this observational study highlight the unacceptably high prevalence of IDH on a day-today basis and that renal nurses need more objective parameters to measure and assess information
prior to and during haemodialysis treatments to evaluate the intravascular volume status.

Relevance to clinical practice
The high occurrence of hypotension related events demonstrates that ultrafiltration treatment goals in
satellite dialysis clinics are sometimes overestimated, resulting in regular significant symptomatic
episodes for the patient. Raising the awareness on the prevalence of IDH amongst renal nurses could
be an essential initial step before collectively preventative strategies in haemodialysis satellite units
are implemented.
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